{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,17]],"date-time":"2026-05-17T04:16:31Z","timestamp":1778991391955,"version":"3.51.4"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2018,5,9]],"date-time":"2018-05-09T00:00:00Z","timestamp":1525824000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Internist"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1007\/s00108-018-0436-z","type":"journal-article","created":{"date-parts":[[2018,5,9]],"date-time":"2018-05-09T12:05:11Z","timestamp":1525867511000},"page":"661-667","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Auswirkungen von Schilddr\u00fcsenfunktionsst\u00f6rungen auf den Knochen","Impact of thyroid diseases on bone"],"prefix":"10.1007","volume":"59","author":[{"given":"E.","family":"Tsourdi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Lademann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Siggelkow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,5,9]]},"reference":[{"key":"436_CR1","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.bone.2008.05.007","volume":"43","author":"JH Bassett","year":"2008","unstructured":"Bassett JH, Williams GR (2008) Critical role of the hypothalamic-pituitary-thyroid axis in bone. Bone 43:418\u2013426","journal-title":"Bone"},{"key":"436_CR2","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1210\/er.2015-1106","volume":"37","author":"JH Bassett","year":"2016","unstructured":"Bassett JH, Williams GR (2016) Role of thyroid hormones in skeletal development and bone maintenance. Endocr Rev 37:135\u2013187","journal-title":"Endocr Rev"},{"key":"436_CR3","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1677\/joe.0.1700667","volume":"170","author":"CH Gouveia","year":"2001","unstructured":"Gouveia CH, Schultz JJ, Bianco AC, Brent GA (2001) Thyroid hormone stimulation of osteocalcin gene expression in ROS 17\/2.8 cells is mediated by transcriptional and post-transcriptional mechanisms. J\u00a0Endocrinol 170:667\u2013675","journal-title":"J Endocrinol"},{"key":"436_CR4","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1007\/s002239900356","volume":"61","author":"F Varga","year":"1997","unstructured":"Varga F, Rumpler M, Luegmayr E et al (1997) Triiodothyronine, a\u00a0regulator of osteoblastic differentiation: depression of histone H4, attenuation of c\u2011fos\/c-jun, and induction of osteocalcin expression. Calcif Tissue Int 61:404\u2013411","journal-title":"Calcif Tissue Int"},{"key":"436_CR5","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1007\/s002230001171","volume":"67","author":"K Banovac","year":"2000","unstructured":"Banovac K, Koren E (2000) Triodothyronine stimulates the release of membrane-bound alkaline phosphatase in osteoblastic cells. Calcif Tissue Int 67:460\u2013465","journal-title":"Calcif Tissue Int"},{"key":"436_CR6","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1006\/bbrc.2002.6561","volume":"291","author":"M Miura","year":"2002","unstructured":"Miura M, Tanaka K, Komatsu Y et\u00a0al (2002) A novel interaction between thyroid hormones and 1,25(OH)(2)D(3) in osteoclast formation. Biochem Biophys Res Commun 291:987\u2013994","journal-title":"Biochem Biophys Res Commun"},{"key":"436_CR7","doi-asserted-by":"publisher","first-page":"3517","DOI":"10.1210\/en.2015-1073","volume":"156","author":"E Tsourdi","year":"2015","unstructured":"Tsourdi E, Rijntjes E, K\u00f6hrle J et al (2015) Hyperthyroidism and hypothyroidism in male mice and their effects on bone mass, bone turnover, and the Wnt inhibitors sclerostin and Dickkopf-1. Endocrinology 156:3517\u20133527","journal-title":"Endocrinology"},{"key":"436_CR8","doi-asserted-by":"publisher","first-page":"3765","DOI":"10.1210\/en.2017-00247","volume":"158","author":"E Tsourdi","year":"2017","unstructured":"Tsourdi E, Lademann F, Ominsky MS et\u00a0al (2017) Sclerostin blockade and zoledronic acid improve bone mass and strength in male mice with exogenous hyperthyroidism. Endocrinology 158:3765\u20133777","journal-title":"Endocrinology"},{"key":"436_CR9","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1530\/eje.0.1450377","volume":"145","author":"M Salerno","year":"2001","unstructured":"Salerno M, Micillo M, Di Maio S et\u00a0al (2001) Longitudinal growth, sexual maturation and final height in patients with congenital hypothyroidism detected by neonatal screening. Eur J Endocrinol 145:377\u2013383","journal-title":"Eur J Endocrinol"},{"key":"436_CR10","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1056\/NEJM198803103181003","volume":"318","author":"SA Rivkees","year":"1988","unstructured":"Rivkees SA, Bode HH, Crawford JD (1988) Long-term growth in juvenile acquired hypothyroidism: the failure to achieve normal adult stature. N\u00a0Engl J Med 318:599\u2013602","journal-title":"N Engl J Med"},{"key":"436_CR11","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1089\/thy.1999.9.871","volume":"9","author":"M Segni","year":"1999","unstructured":"Segni M, Leonardi E, Mazzoncini B (1999) Special features of Graves\u2019 disease in early childhood. Thyroid 9:871\u2013877","journal-title":"Thyroid"},{"key":"436_CR12","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s40618-017-0753-4","volume":"41","author":"GR Williams","year":"2018","unstructured":"Williams GR, Bassett JHD (2018) Thyroid diseases and bone health. J\u00a0Endocrinol Invest 41:99\u2013109","journal-title":"J Endocrinol Invest"},{"key":"436_CR13","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/8756-3282(86)90681-2","volume":"7","author":"EF Eriksen","year":"1986","unstructured":"Eriksen EF, Mosekilde L, Melsen F (1986) Kinetics of trabecular bone resorption and formation in hypothyroidism: evidence for a\u00a0positive balance per remodeling cycle. Bone 7:101\u2013108","journal-title":"Bone"},{"key":"436_CR14","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1089\/105072502760043503","volume":"12","author":"P Vestergaard","year":"2002","unstructured":"Vestergaard P, Mosekilde L (2002) Fractures in patients with hyperthyroidism and hypothyroidism: a\u00a0nationwide follow-up study in 16,249 patients. Thyroid 12:411\u2013419","journal-title":"Thyroid"},{"key":"436_CR15","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s00223-005-0068-x","volume":"77","author":"P Vestergaard","year":"2005","unstructured":"Vestergaard P, Rejnmark L, Mosekilde L (2005) Influence of hyper- and hypothyroidism, and the effects of treatment with antithyroid drugs and levothyroxine on fracture risk. Calcif Tissue Int 77:139\u2013144","journal-title":"Calcif Tissue Int"},{"key":"436_CR16","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S0889-8529(18)30338-4","volume":"19","author":"L Mosekilde","year":"1990","unstructured":"Mosekilde L, Eriksen EF, Charles P (1990) Effects of thyroid hormones on bone and mineral metabolism. Endocrinol Metab Clin North Am 19:35\u201363","journal-title":"Endocrinol. Metab. Clin. North. Am."},{"key":"436_CR17","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1210\/jc.2010-2135","volume":"96","author":"SP Bours","year":"2011","unstructured":"Bours SP, van Geel TA, Geusens PP et\u00a0al (2011) Contributors to secondary osteoporosis and metabolic bone diseases in patients presenting with a\u00a0clinical fracture. J\u00a0Clin Endocrinol Metab 96:1360\u20131367","journal-title":"J Clin Endocrinol Metab"},{"key":"436_CR18","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1210\/jc.2009-1625","volume":"95","author":"RW Flynn","year":"2010","unstructured":"Flynn RW, Bonellie SR, Jung RT et al (2010) Serum thyroid-stimulating hormone concentration and morbidity from cardiovascular disease and fractures in patients on long-term thyroxine therapy. J\u00a0Clin Endocrinol Metab 95:186\u2013193","journal-title":"J Clin Endocrinol Metab"},{"key":"436_CR19","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1530\/acta.0.0850515","volume":"85","author":"L Mosekilde","year":"1977","unstructured":"Mosekilde L, Melsen F, Bagger JP et al (1977) Bone changes in hyperthyroidism: interrelationships between bone morphometry, thyroid function and calcium-phosphorus metabolism. Acta Endocrinol 85:515\u2013525","journal-title":"Acta. Endocrinol."},{"key":"436_CR20","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1210\/jcem.85.3.6457","volume":"85","author":"H Pantazi","year":"2000","unstructured":"Pantazi H, Papapetrou PD (2000) Changes in parameters of bone and mineral metabolism during therapy for hyperthyroidism. J\u00a0Clin Endocrinol Metab 85:1099\u20131106","journal-title":"J Clin Endocrinol Metab"},{"key":"436_CR21","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1089\/105072503322238854","volume":"13","author":"P Vestergaard","year":"2003","unstructured":"Vestergaard P, Mosekilde L (2003) Hyperthyroidism, bone mineral, and fracture risk\u2014a meta-analysis. Thyroid 13:585\u2013593","journal-title":"Thyroid"},{"key":"436_CR22","first-page":"1531","volume":"75","author":"CJ Rosen","year":"1992","unstructured":"Rosen CJ, Adler RA (1992) Longitudinal changes in lumbar bone density among thyrotoxic patients after attainment of euthyroidism. J\u00a0Clin Endocrinol Metab 75:1531\u20131534","journal-title":"J Clin Endocrinol Metab"},{"key":"436_CR23","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1001\/jama.2015.5161","volume":"313","author":"MR Blum","year":"2015","unstructured":"Blum MR, Bauer DC, Collet TH et al (2015) Subclinical thyroid dysfunction and fracture risk: a\u00a0meta-analysis. JAMA 313:2055\u20132065","journal-title":"JAMA"},{"key":"436_CR24","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s00774-017-0828-5","volume":"36","author":"R Yang","year":"2018","unstructured":"Yang R, Yao L, Fang Y et al (2018) The relationship between subclinical thyroid dysfunction and the risk of fracture or low bone mineral density: a\u00a0systematic review and meta-analysis of cohort studies. J\u00a0Bone Miner Metab 36:209\u2013220","journal-title":"J Bone Miner Metab"},{"key":"436_CR25","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1002\/jbmr.2244","volume":"29","author":"B Abrahamsen","year":"2015","unstructured":"Abrahamsen B, Jorgensen HL, Laulund AS et al (2015) Low serum thyrotropin level and duration of suppression as a\u00a0predictor of major osteoporotic fractures-the OPENTHYRO register cohort. J\u00a0Bone Miner Res 29:2040\u20132050","journal-title":"J Bone Miner Res"},{"key":"436_CR26","first-page":"4318","volume":"81","author":"P Pujol","year":"1996","unstructured":"Pujol P, Daures JP, Nsakala N et\u00a0al (1996) Degree of thyrotropin suppression as a\u00a0prognostic determinant in differentiated thyroid cancer. J\u00a0Clin Endocrinol Metab 81:4318\u20134323","journal-title":"J Clin Endocrinol Metab"},{"key":"436_CR27","first-page":"4278","volume":"81","author":"B Uzzan","year":"1996","unstructured":"Uzzan B, Campos J, Cucherat M et al (1996) Effects on bone mass of long term treatment with thyroid hormones: a\u00a0meta-analysis. J\u00a0Clin Endocrinol Metab 81:4278\u20134289","journal-title":"J Clin Endocrinol Metab"},{"key":"436_CR28","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1530\/eje.0.1300350","volume":"130","author":"J Faber","year":"1994","unstructured":"Faber J, Galloe AM (1994) Changes in bone mass during prolonged subclinical hyperthyroidism due to l\u2011thyroxine treatment: a\u00a0meta-analysis. Eur J Endocrinol 130:350\u2013356","journal-title":"Eur J Endocrinol"},{"key":"436_CR29","doi-asserted-by":"publisher","first-page":"561","DOI":"10.7326\/0003-4819-134-7-200104030-00009","volume":"134","author":"DC Bauer","year":"2001","unstructured":"Bauer DC, Ettinger B, Nevitt MC et al (2001) Risk for fracture in women with low serum levels of thyroid-stimulating hormone. Ann Intern Med 134:561\u2013568","journal-title":"Ann Intern Med"},{"key":"436_CR30","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1007\/s40618-014-0110-9","volume":"37","author":"GR Williams","year":"2014","unstructured":"Williams GR (2014) Is prophylactic anti-resorptive therapy required in thyroid cancer patients receiving TSH-suppressive treatment with thyroxine? J\u00a0Endocrinol Invest 37:775\u2013779","journal-title":"J Endocrinol Invest"}],"container-title":["Der Internist"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00108-018-0436-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-018-0436-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-018-0436-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,8]],"date-time":"2019-05-08T23:26:30Z","timestamp":1557357990000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00108-018-0436-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,9]]},"references-count":30,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["436"],"URL":"https:\/\/doi.org\/10.1007\/s00108-018-0436-z","relation":{},"ISSN":["0020-9554","1432-1289"],"issn-type":[{"value":"0020-9554","type":"print"},{"value":"1432-1289","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,9]]},"assertion":[{"value":"9 May 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"E.\u00a0Tsourdi erhielt Honorare f\u00fcr Vortr\u00e4ge von Amgen. F.\u00a0Lademann gibt an, dass kein Interessenkonflikt besteht. H.\u00a0Siggelkow erhielt Honorare f\u00fcr Vortr\u00e4ge von MSD, GSK, Amgen, Servier, Lilly und Shire sowie Beraterhonorare von MSD, Lilly, Amgen, Servier und Shire.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"Dieser Beitrag beinhaltet keine von den Autoren durchgef\u00fchrten Studien an Menschen oder Tieren.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}}]}}